These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 17239996

  • 1. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 2. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [Abstract] [Full Text] [Related]

  • 3. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S.
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [Abstract] [Full Text] [Related]

  • 6. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
    Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus Ch, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J.
    Mol Psychiatry; 2010 Feb; 15(2):138-45. PubMed ID: 18663368
    [Abstract] [Full Text] [Related]

  • 7. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [Abstract] [Full Text] [Related]

  • 14. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S.
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [Abstract] [Full Text] [Related]

  • 15. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
    Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ.
    Neurology; 2007 Aug 14; 69(7):631-9. PubMed ID: 17698783
    [Abstract] [Full Text] [Related]

  • 16. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K.
    J Alzheimers Dis; 2010 Aug 14; 22(4):1281-8. PubMed ID: 20930282
    [Abstract] [Full Text] [Related]

  • 17. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
    J Alzheimers Dis; 2010 Aug 14; 21(2):471-8. PubMed ID: 20555147
    [Abstract] [Full Text] [Related]

  • 18. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):124-8. PubMed ID: 17097109
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
    Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP.
    Neurobiol Aging; 2008 Aug 21; 29(8):1143-59. PubMed ID: 17428581
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ.
    Arch Neurol; 2003 Dec 21; 60(12):1696-702. PubMed ID: 14676043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.